A person's 'bioenergetic age' -- or how youthfully their cells generate energy -- might be a key indicator of whether they're at risk of developing Alzheimer's disease, new research shows. The study ...

Researchers have discovered that a person's "bioenergetic age," reflecting how efficiently cells produce energy, strongly ...

A person’s “bioenergetic age”, or how youthfully their cells generate energy, might be a key indicator of whether they’re at ...

Why are researchers still fumbling in the quest to cure what is arguably one of the most important diseases confronting ...

Scientists have discovered that how well a person’s cells generate energy—what they call “bioenergetic age”—could be a strong ...

The National Institute for Health and Care Excellence (NICE) has decided to reconsult on draft guidance for Alzheimer’s treatments donanemab and lecanemab, six months after initially rejecting the ...

The Japanese pharma company – currently in the process of rolling out new amyloid-targeting Alzheimer's therapy Leqembi ...

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...

We respond to the disappointing decision NICE has made to not recommend donanemab and lecanemab on the NHS. On Thursday, 6 March, NICE published further draft guidance for public consultation that ...

Health chiefs were today urged to reconsider approving a breakthrough Alzheimer's drug proven to tackle the devastating disease on the NHS. Lecanemab and donanemab were hailed as 'the beginning ...

Additional evidence has prompted NICE to launch a second consultation on its decision not to recommend new Alzheimer’s ...

Today we’ve published further draft guidance for public consultation that continues to not recommend Alzheimer’s treatments donanemab and lecanemab. These cookies remember information that changes the ...